CL2024001850A1 - Complejos polipeptídicos de unión a antígeno activados condicionalmente y métodos de uso de los mismos. - Google Patents

Complejos polipeptídicos de unión a antígeno activados condicionalmente y métodos de uso de los mismos.

Info

Publication number
CL2024001850A1
CL2024001850A1 CL2024001850A CL2024001850A CL2024001850A1 CL 2024001850 A1 CL2024001850 A1 CL 2024001850A1 CL 2024001850 A CL2024001850 A CL 2024001850A CL 2024001850 A CL2024001850 A CL 2024001850A CL 2024001850 A1 CL2024001850 A1 CL 2024001850A1
Authority
CL
Chile
Prior art keywords
polypeptide complexes
antigen
methods
binding polypeptide
conditionally activated
Prior art date
Application number
CL2024001850A
Other languages
English (en)
Spanish (es)
Inventor
Xu Ling
J Nabel Gary
GRECI Mark
Chen Hao
Wu Lan
Seung Edward
Yang Zhi-Yong
R Wei Ronnie
Zerhouni Elias
Jones Nicholas
Original Assignee
Modex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modex Therapeutics Inc filed Critical Modex Therapeutics Inc
Publication of CL2024001850A1 publication Critical patent/CL2024001850A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2024001850A 2021-12-21 2024-06-19 Complejos polipeptídicos de unión a antígeno activados condicionalmente y métodos de uso de los mismos. CL2024001850A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163292382P 2021-12-21 2021-12-21

Publications (1)

Publication Number Publication Date
CL2024001850A1 true CL2024001850A1 (es) 2025-02-21

Family

ID=86903785

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001850A CL2024001850A1 (es) 2021-12-21 2024-06-19 Complejos polipeptídicos de unión a antígeno activados condicionalmente y métodos de uso de los mismos.

Country Status (13)

Country Link
US (1) US20240059798A1 (https=)
EP (1) EP4452317A4 (https=)
JP (1) JP2025503480A (https=)
KR (1) KR20240134257A (https=)
CN (4) CN118251411A (https=)
AR (1) AR128060A1 (https=)
AU (1) AU2022420594A1 (https=)
CA (1) CA3240079A1 (https=)
CL (1) CL2024001850A1 (https=)
IL (1) IL313770A (https=)
MX (1) MX2024007393A (https=)
TW (1) TW202334204A (https=)
WO (1) WO2023122659A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2025249301A1 (ja) * 2024-05-27 2025-12-04 国立大学法人東京農工大学 多重特異性抗体、がん増殖抑制剤、ポリヌクレオチド及び発現ベクター
CN121248779A (zh) * 2024-06-25 2026-01-02 冕屹立生物技术(上海)有限公司 靶向人cd3分子的抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI743461B (zh) * 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US9458244B2 (en) * 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
RS62437B1 (sr) * 2015-10-25 2021-11-30 Sanofi Sa Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
CA3020633A1 (en) * 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
WO2018075564A1 (en) * 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
BR112020016944A2 (pt) * 2018-02-20 2020-12-15 Dragonfly Therapeutics, Inc. Domínios variáveis de anticorpo que alvejam cd33 e uso dos mesmos
MX2021000307A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética.
US12365722B2 (en) * 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
AU2019372673A1 (en) * 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
US11613576B2 (en) * 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白
TW202330594A (zh) * 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
IL313617A (en) * 2021-12-17 2024-08-01 Modex Therapeutics Inc Antigen-binding polypeptide complexes containing extracellular regions of TNFSF ligands

Also Published As

Publication number Publication date
CN118251411A (zh) 2024-06-25
TW202334204A (zh) 2023-09-01
EP4452317A4 (en) 2025-12-10
US20240059798A1 (en) 2024-02-22
EP4452317A2 (en) 2024-10-30
WO2023122659A2 (en) 2023-06-29
CN118715247A (zh) 2024-09-27
WO2023122659A3 (en) 2023-08-03
CA3240079A1 (en) 2023-06-29
KR20240134257A (ko) 2024-09-06
JP2025503480A (ja) 2025-02-04
MX2024007393A (es) 2024-07-04
CN118591388A (zh) 2024-09-03
AU2022420594A1 (en) 2024-08-01
CN118317979A (zh) 2024-07-09
AR128060A1 (es) 2024-03-20
IL313770A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
CL2024001850A1 (es) Complejos polipeptídicos de unión a antígeno activados condicionalmente y métodos de uso de los mismos.
CL2024000896A1 (es) Polipéptidos de unión a antígeno, complejos y métodos de uso de los mismo.
PE20220231A1 (es) Proteinas de fusion flt3l-fc y metodos de uso
BR112021016984A2 (pt) Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
BR112022001368A2 (pt) Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
PY1888702A (es) Anticuerpos anti-cd38 y métodos de uso
MX2021003608A (es) Moleculas de union a antigeno capaces de unirse al cumulo de diferenciacion 3 (cd3) y al cumulo de diferenciacion 137 (cd137) pero no simultaneamente.
BR112019010349A2 (pt) Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores
CL2016001134A1 (es) Celula t o celula asesina natural (nk) que expresa dos receptores de antigeno quimerico (car), donde un car comprende un endodominio activador y el otro un dominio inhibitorio de proteina tirosina fosfatasa que contiene el dominio src (sh2); acido nucleico; vector; metodo de produccion; composicion; uso para preparar medicamento.
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40
AR120822A1 (es) Agentes de unión a ilt3 y sus métodos de uso
PE20240761A1 (es) Proteinas de union a psma y usos de estas
PL422231A1 (pl) Komórki immunologiczne CAR do leczenia nowotworów
CL2024001751A1 (es) Complejos polipeptídicos de unión a antígeno que contienen dominios extracelulares de ligandos tnfsf
CO2025017440A2 (es) Anticuerpos de dominio único modificados
CO2022008314A2 (es) Anticuerpos anti–mertk y métodos de uso de los mismos
CL2024000890A1 (es) Polipéptidos de unión a antígeno, complejos de polipéptidos de unión a antígeno y métodos de uso de los mismos en el vih
MX2024011781A (es) Agentes de union a ilt3 y cd3 y metodos de uso de estos
CL2025001723A1 (es) Composiciones de agentes de unión a antígenos de guanilato ciclasa c (gcc) y métodos de uso de estos.
AR119468A1 (es) Proteínas que comprenden dominios de unión antígeno de la peptidasa 2 relacionados con la calicreína y sus usos
AR113757A1 (es) Anticuerpos anti-cd38 y métodos de uso
AR112758A1 (es) Anticuerpos agonistas que unen cd137 humano, y usos de los mismos
AR133126A2 (es) Fragmentos de anticuerpos con bisagra modificada y métodos de preparación de los mismos
AR119982A1 (es) Terapias de combinación con anticuerpos entpd2
AR109825A1 (es) ANTICUERPOS DE INTERFERÓN b Y USOS DE LOS MISMOS